Families and NHS count cost of cancer diagnosis failures

By the Editorial Team · Thursday, July 23, 2026

The NHS in England has paid nearly £190 million over five years to settle 870 claims related to missed or delayed cancer diagnoses, with annual costs rising to an estimated £41.3 million by 2024-25. These diagnostic failures lead to advanced-stage cancers requiring more intensive treatment, worsening patient outcomes, and prompting increased legal and financial burdens amid ongoing challenges in meeting cancer treatment targets.

A new analysis of settlements related to cancer diagnosis failures has revealed significant financial and human costs for the National Health Service (NHS) in England. Over the past five years, the NHS has paid nearly £190 million to resolve 870 claims involving either misdiagnosis or delayed diagnosis of cancer, with overall annual costs—including legal fees—rising from £32 million in 2020-21 to an estimated £41.3 million in 2024-25.

The case of Helen Dutton, a finance manager and mother of one from Greater Manchester, highlights the profound consequences of such failures. Dutton first sought medical advice in late 2016 after experiencing symptoms such as back pain, rectal bleeding, and changes in bowel habits. At that time, her general practitioner diagnosed her with irritable bowel syndrome and haemorrhoids and did not refer her for cancer testing. It was not until two years later, when she consulted a different GP, that she underwent scans and a colonoscopy revealing advanced rectal cancer, already at stage 4.

Dutton underwent chemotherapy, radiotherapy, and surgery and was declared cancer free in June 2020. However, her cancer returned within two months, and she passed away in 2021 at age 40. Her partner, Darren Rosheski, said the initial failure to investigate her symptoms sooner severely diminished her chances of survival. He successfully sued for an undisclosed settlement, though the NHS did not admit liability.

According to solicitor Olivia Boschat, the rising number and cost of claims highlight the devastating personal impact of diagnostic errors. “Some delays are unavoidable, but others result from symptoms being overlooked, tests not being promptly conducted, or results not acted upon,” she said. These lapses can allow cancer to progress to later stages, necessitating more aggressive treatment and reducing survival prospects.

Last year, the NHS settled 171 claims, fewer than in prior years. However, the average settlement amount has increased from approximately £200,000 in 2020-21 to over £240,000 in 2024-25, a 20% rise. The growing financial liability reflects the severity of cases brought forward and the ongoing challenge of ensuring early cancer diagnosis.

The NHS has struggled to meet key government targets for cancer treatment timelines. Since December 2020, it has consistently missed the goal of starting urgent cancer treatment within 31 days of agreeing on a treatment plan. Furthermore, the two-month target from hospital referral to treatment has not been met since 2015.

The Department of Health and Social Care acknowledged that errors occur but emphasized efforts to improve early detection. A spokesperson noted that in the previous year, 82,000 more people received timely cancer diagnoses or reassurance than the year before. Initiatives such as “Jess’s rule,” which encourages GPs to seek a second opinion on diagnostic doubts, and the rollout of digital tools aim to enhance early flagging of concerning symptoms.

Experts warn that delayed or missed cancer diagnoses have profound effects on patients and their families. Guy Forster, president of the Association of Personal Injury Lawyers, highlighted the emotional and financial toll on bereaved families who lose vital support following avoidable diagnostic delays.

This article was reported by synthesizing coverage from multiple independent news outlets to present a balanced, unbiased account. Read about our editorial standards. Spotted an error? Let us know.